Assignee
Numab Therapeutics AG
CH·13 granted patents·14 pending applications·2 citations·filing 2016–2024
Top patents by PatentIndex Score
27 records- 0174US2023212265A1Novel antibody frameworksNumab Therapeutics AG·Filed 2022·Application pending·0 cites
- 0273US11319371B2Anti-CD3 antibodiesNumab Therapeutics AG·Filed 2018·Granted May 3, 2022·1 cites·16 claims
- 0373US11236150B2Hetero-dimeric multi-specific antibody formatNumab Therapeutics AG·Filed 2016·Granted Feb 1, 2022·1 cites·17 claims
- 0470US2025066482A1Antibodies targeting pdl1 and methods of use thereofNumab Therapeutics AG·Filed 2024·Application pending·0 cites
- 0568US11879005B2Hetero-dimeric multi-specific antibody formatNumab Therapeutics AG·Filed 2022·Granted Jan 23, 2024·0 cites·17 claims
- 0666US11427628B2Antibody frameworksNumab Therapeutics AG·Filed 2018·Granted Aug 30, 2022·0 cites·4 claims
- 0763US2023242651A1Stable antibody variable domain framework combinationsNumab Therapeutics AG·Filed 2022·Application pending·0 cites
- 0862US2022403028A1Novel anti-cd3 antibodiesNumab Therapeutics AG·Filed 2022·Application pending·0 cites
- 0958US12077588B2Antibodies targeting PDL1 and methods of use thereofNumab Therapeutics AG·Filed 2018·Granted Sep 3, 2024·0 cites·28 claims
- 1056US2025282880A1Antibody variable domains that bind il-4rNumab Therapeutics AG·Filed 2021·Application pending·0 cites
- 1156US2024043547A1Antibody variable domains that bind il-31Numab Therapeutics AG·Filed 2021·Application pending·0 cites
- 1255US2018282419A1Bispecific Constructs and Their Use in the Treatment of Various DiseasesNumab Therapeutics AG·Filed 2018·Application pending·0 cites
- 1354US2025382363A1Antibody Variable Domains And Antibodies Having Decreased ImmunogenicityNumab Therapeutics AG·Filed 2023·Application pending·0 cites
- 1454US2023391882A1Combination treatmentNumab Therapeutics AG·Filed 2021·Application pending·0 cites
- 1553US12209133B2Antibodies targeting CD137 and methods of use thereofNumab Therapeutics AG·Filed 2019·Granted Jan 28, 2025·0 cites·25 claims
- 1652US11421035B2Stable antibody variable domain framework combinations and methods of use thereofNumab Therapeutics AG·Filed 2018·Granted Aug 23, 2022·0 cites·28 claims
- 1751US12202911B2Multispecific antibody comprising CD137 binding domain and PDL1 binding domainNumab Therapeutics AG·Filed 2018·Granted Jan 21, 2025·0 cites·3 claims
- 1851US11578133B2Antibodies targeting CD137 and methods of use thereofNumab Therapeutics AG·Filed 2018·Granted Feb 14, 2023·0 cites·15 claims
- 1950US12503505B2Multispecific antibodies having specificity for TNFα and IL-17A, antibodies targeting IL-17A, and methods of use thereofNumab Therapeutics AG·Filed 2020·Granted Dec 23, 2025·0 cites·28 claims
- 2050US2025282879A1Multispecific antibodies having specificity for il-4r and il-31Numab Therapeutics AG·Filed 2021·Application pending·0 cites
- 2150US2024392003A1Multispecific antibodies having specificity for ror1 and cd3Numab Therapeutics AG·Filed 2022·Application pending·0 cites
- 2249US2023203162A1Multispecific antibodyNumab Therapeutics AG·Filed 2021·Application pending·0 cites
- 2346US2022411536A1Multispecific antibodyNumab Therapeutics AG·Filed 2020·Application pending·0 cites
- 2444US10774140B2Anti-TNFα-antibodies and functional fragments thereofNumab Therapeutics AG·Filed 2017·Granted Sep 15, 2020·0 cites·16 claims
- 2544US2024084039A1Antibody variable domains and antibodies having decreased immunogenicityNumab Therapeutics AG·Filed 2021·Application pending·0 cites
- 2642US12098203B2Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSANumab Therapeutics AG·Filed 2018·Granted Sep 24, 2024·0 cites·25 claims
- 2738US11365240B2Anti-HSA antibodiesNumab Therapeutics AG·Filed 2018·Granted Jun 21, 2022·0 cites·12 claims
Join the waitlist — get patent alerts
Get an alert when Numab Therapeutics AG files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →